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Abstract
The mitogen-activated protein kinase (MAPK) ERK2 is ubiquitously expressed in mammalian
tissues and is involved in a wide range of biological processes. Although MAPKs have been
intensely studied, identification of their substrates remains challenging. We have optimized a
chemical genetic system using analog-sensitive ERK2,a form of ERK2 engineered to utilize an
analog of ATP, to tag and isolate ERK2 substrates in vitro. This approach identified 80 proteins
phosphorylated by ERK2, 13 of which are known ERK2 substrates. The 80 substrates are
associated with diverse cellular processes, including regulation of transcription and translation,
and mRNA processing, as well as regulation of the activity of the Rho-family guanosine
triphosphatases. We found that one of the newly identified substrates, ETV3 (a member of the E-
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twenty six family of transcriptional regulators) was extensively phosphorylated on sites within
canonical and non-canonical ERK motifs. Phosphorylation of ETV3 regulated transcription by
preventing its binding to DNA at promoters for several thousand genes, including some involved
in negative feedback regulation of itself and of upstream signals.
Introduction
Much of the signal processing in eukaryotes involves protein phosphorylation by networks
of kinases and phosphatases. Mitogen-activated protein kinases (MAPKs) are serine/
threonine kinases that are conserved from yeast to human and represent an integral part of
this network (1). In particular, the extracellular-signal regulated kinases 1 and 2 (ERK1/2)
are ubiquitously expressed in mammalian cells and involved in many biological processes,
including development (2), glucose homeostasis (3), immune function (4), and memory (5).
Deregulation of ERK1/2 activity is common in cancer and leads to proliferation, migration,
resistance to apoptosis, and loss of differentiated phenotypes (6).
ERK1/2 regulates these various biological processes by phosphorylating hundreds of
substrate proteins (7). Substrate recognition is mediated by protein-protein docking sites,
and the substrate binding cleft allows for serine or threonine phosphorylation within an
amino acid motif with proline strongly preferred at the +1 and common at −2 positions (8).
ERK activity and substrate specificity is further regulated by scaffolds and adaptors that
assemble the MAPK kinase kinase Raf to MAPK kinase MEK to ERK activation cascade
and direct subcellular localization (9). Even though many ERK substrates have been
identified, incomplete knowledge of ERK targets remains a hurdle to understanding the
myriad biological consequences of ERK activity.
To understand how ERK2 regulates diverse biological responses to cellular stimuli, we
sought to identify direct ERK2 substrates and determine quantitative substrate utilization
under different biological contexts. However, elucidating enzyme-substrate interactions
among signaling molecules is difficult because many substrates are extremely low
abundance, interactions are often transient, phosphorylation stoichiometry may be low, and
residues are often phosphorylated by several kinases. Moreover, targeted genetic
knockdown or chemical inhibition may lead to pleiotropic effects due to complex feedback
and crosstalk within signaling networks (10). Despite these concerns, several groups have
used global quantitative phosphoproteomics to characterize ERK1/2 signaling by identifying
phosphorylation sites that respond to MEK inhibition (10–13).Among these groups, Kosako
et al. used a combination of affinity chromatography and 2D gel electrophoresis to identify
MEK-dependent phosphorylation sites, including 24 potential ERK targets, many of which
were biochemically validated as direct ERK1/2 substrates (13). However, phosphoprotein
analysis by itself does not establish direct kinase/substrate relationships and is inherently
limited by the dynamic range between abundant phosphorylated proteins and low-abundance
substrates. An alternative approach is to selectively tag and enrich direct kinase substrates,
allowing more sensitive detection of direct substrates by reducing the background of
proteins phosphorylated by other kinases.
Analog-sensitive kinases (AS-kinases) can accommodate unnatural ATP analogs through an
expanded ATP-binding pocket; these engineered proteins have been used to identify direct
kinase/substrate interactions for several kinases (14). AS-kinases retain their natural
substrate specificity. For instance, ERK2 with Q103G substitution (AS-ERK2) uses ATP
and ATP analogs efficiently and interacts with known ERK2 substrates (15), and an AS
form of cyclin-dependent kinase 2 (AS-CDK2) retains the kinetics and substrate specificity
of the wild-type protein (16). Radioactive tagging on γ-phosphate of the ATP analog was
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originally used for selective labeling and detection of AS-kinase substrates, but purification
and identification remained problematic. Two procedures have been reported that use γ-
thiol-phosphate ATP analogs to thiophosphorylate substrates of cyclin/CDK complexes in
whole cell lysates (17, 18). In both cases, the thiophosphate serves as a nucleophilic
“handle” to purify peptides from tryptic digests so that substrates can be identified by
tandem mass spectrometry (MS/MS). These experiments rely on the unique ability of the
AS-kinase to bind and utilize the ATP analog; any non-specific utilization of the ATP
analog by other kinases in the cell will increase the background and may lead to false-
positive substrate identification.
AS-ERK2 was used to identify the ubiquitin ligase EDD and nucleoporin TPR as direct
substrates but discovery of additional targets has been limited by their low abundance (15).
To address this issue, we have optimized the solid-phase capture of thiophosphorylated
peptides and added an additional phosphopeptide enrichment to reduce background, thereby
enabling low-level substrate identification. Additionally, we have incorporated quantitative
mass spectrometry using stable isotope labeling in cell culture (SILAC) (19) to establish
statistical thresholds for identification of substrates over background phosphorylation,
thereby decreasing false-positive substrate identification. This approach is generally
applicable to all AS-kinases.
With this improved methodology, we detected 98 sites directly phosphorylated by ERK2 on
80 proteins from NIH 3T3-L1 fibroblasts. Thirteen of these proteins are known substrates
and the rest represent previously unknown kinase/substrate interactions (7).These results
reveal a diverse and largely unknown set of substrates, and show that that ERK2 acts on a
much broader range of targets than previously recognized. Among the ERK2 substrates, we
identified the E-twenty six (ETS) domain-containing protein ETV3. We determined that
phosphorylation of this protein by ERK2 was functionally relevant, abrogating the DNA-
binding activity of ETV3 at thousands of targets across the genome, thereby providing an
additional mechanism for transcriptional regulation downstream of ERK2 activation.
Results
Improved method for solid-phase capture of thiophosphorylated AS-kinase substrates
To identify direct substrates of AS-kinases, we began with the method originally developed
by Allen et al. (20) and Blethrow et al. (17), in which thiophosphorylated substrate peptides
are captured on a solid-phase agarose support functionalized with iodo-acetyl groups, then
released by oxidative hydrolysis to yield phosphorylated peptides. We found that oxidative
hydrolysis of bead-conjugated thiophosphopeptides released non-specifically adsorbed, non-
phosphorylated peptides that can interfere with identification of low-abundance substrates.
To reduce the amount of the non-phosphorylated background peptides, we included an
additional phosphopeptide enrichment using immobilized metal affinity chromatography
(IMAC) (21). We also determined that selective capture of thiophosphorylated peptides was
enhanced if the pH of the thiophosphate coupling reaction was decreased to 5.5, from 7.0
used by Blethrow et al, to favor binding of thiophosphate over cysteine. The final protocol is
schematically represented in Fig. 1A (a detailed protocol is available in the Supplementary
Methods).
Because the AS-kinase approach relies on the selective affinity of the AS-kinase for ATP
analogs, we confirmed the selective utilization of PhEt-ATPγS by AS-ERK2 relative to
wild-type ERK2 (WT-ERK2) by an in vitro kinase reaction using PhEt-ATPγS (Fig. 1B). To
test specificity of labeling in the context of a whole cell lysate, we expressed matched
amounts of AS-ERK2 and WT-ERK2 in NIH 3T3-L1 cells and conducted in vitro reactions
in lysate of cells treated with phorbol-12-myristate-13-acetate (PMA). As expected, labeling
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was strongest in the presence of AS-ERK2, and was decreased by pre-treatment with the
MEK inhibitor U0126 (Fig. 1C, D). We also detected labeling in control cells expressing
WT-ERK2, indicating utilization of PhEt-ATPγS by wild-type kinases (Fig. 1C, D). The
cumulative non-specific labeling by endogenous kinases indicated that a quantitative
approach to measuring non-specific labeling was necessary to resolve low abundance
substrates from background signals.
Identification of Q103G–ERK2 (AS-ERK2) substrates
To distinguish phosphorylated ERK2 substrates from non-specific background
phosphorylation, we used SILAC for quantitative comparison between AS-ERK2 and WT-
ERK2 cell lysates. Cells expressing AS-ERK2 were grown in “heavy” L-arginine and L-
lysine labeled with 13C or 13C and 15N, whereas WT-ERK2 cells were grown in L-arginine
and L-lysine containing entirely 12C and 14N. Samples were combined after in vitro kinase
reactions and prior to tryptic digestion. The resulting peptides have distinctive mass
signatures: Background peptides have light and heavy ion signals with similar intensity,
whereas ERK2 substrate peptides are enriched for heavy ions.
We combined this SILAC quantitative approach with our solid-phase capture protocol to
identify thiophosphorylated peptides from six independent labeling reactions with lysates of
epidermal growth factor (EGF)-stimulated 3T3-L1 cells expressing WT-ERK2 or AS-
ERK2. We used MASCOT (22) to match MS/MS spectra to phosphorylated peptides and
examined the results for peptides matching the minimal ERK2 substrate motif: pSer or pThr
followed by proline. The MS/MS spectra for all potential ERK2 substrates were manually
inspected to ensure proper placement of the phosphorylated residue (Supplementary
spectra), and validation with synthetic peptides was used to confirm any low-confidence
assignment.
We detected phosphorylated peptides from thirteen reported substrates: Cx43,DYNC1I2,
DYNC1LI1, EGFR, ERF, KSR, LMNA, MAPKAP2, NUP153, TPR, STMN1, RPS3, and
SORBS3 (7, 13). (A complete annotated list, including the complete names, of all identified
ERK2 substrates are provided as table S1.) To differentiate AS-ERK2 substrates from
background phosphorylation, we used these thirteen substrates to set a threshold for the
quantitative difference in phosphorylation between the AS-ERK2-and WT-ERK2-
expressing cells. Signal-over-background ratios for known ERK2 substrates ranged from 6%
to 33% (Table 1), whereas non-specific peptides had ratios around 100% with a standard
deviation (S.D.) of 19%. Because residual light amino acids in heavy-labeled cells were less
than 2%, we concluded that ERK2 substrate sites were subject to varying degrees of non-
specific labeling. This result highlights the importance of quantitatively analyzing the
negative control to distinguish background from bona fide substrates. To evaluate
approximately 200 potential ERK2 substrates, we set a threshold of 3.5 standard deviations
below 100% in log-space, corresponding to a light:heavy ratio of 47% and a Bonferroni-
corrected familywise error rate of 0.05,assuming that ratios are log-normal distributed under
the null-hypothesis.
A total of 98 peptides from 80 proteins met the criteria for in vitro ERK2 substrates,
including 67 previously uncharacterized ERK2 substrates. Fig. 1E shows representative
SILAC mass signatures for several phosphorylated peptides. Three phosphopeptides
matched the consensus ERK2 motif but had light to heavy ratios close to 100% (ATF7,
HIVEP1, G3BP-1), suggesting that these were nonspecific events. In agreement with our
data, ATF7 phosphorylation does not respond to MEK inhibition in HeLa cells despite its
homology to ATF2 Thr53 (position 71 in human), a well-known ERK2 substrate site (23).
Without quantitative data, these peptides could have been mistaken as ERK2 substrates.
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As expected based on the complex circuitry of the ERK2 network, we identified substrates
that spanned a range of both upstream and downstream signaling pathways across many
biological processes (Fig. 2A). These substrates were associated with multiple cellular
compartments, including the cytoplasm, nucleus, and membrane, among other compartments
and organelles (Fig. 2B).
Validating AS-ERK2 substrate specificity
To determine whether the newly identified substrates were consistent with known ERK1/2
binding motifs, we used ScanSite to search the substrates for ERK binding sequences: D-
domains (positively charged residues three to five residues ahead of a hydrophobic
sequence) and DEF-domains (FXFP, where X is any amino acid and Y may substitute for F)
(24). Both motifs were strongly enriched in the AS-ERK2 substrates compared to the
SwissProt mouse proteome (Fig. 3A). We also compared phosphorylation site motifs for
AS-ERK2 substrates with known ERK2 substrates according to PhosphoSite
(www.phosphosite.org) and found that major features of the two motifs were identical (Fig
3B). Although most detected substrates matched the minimal ERK1/2 consensus motif SP/
TP, and many matched the full PXSP/PXTP motif, these motifs were neither necessary nor
sufficient to identify ERK2 substrates. In fact, one substrate phosphorylation site on the
transcriptional repressor ETV3 was found that lacks the adjacent proline in the +1 position.
Although the ERK2 Q103G mutation has no effect on substrate specificity (15), we tested
several of the substrates identified in this study for phosphorylation by WT-ERK2. Each of
the seven recombinant substrate proteins was phosphorylated in vitro by ERK2 to varying
degrees (Fig. 3C). We also mapped phosphorylation of recombinant CDC42EP1, IRS2 and
ETV3 by mass spectrometry following in vitro kinase reactions using wild-type ERK2 and
identified additional ERK2-dependent phosphorylation site son each protein (Fig. 4A, fig.
S1).
In vivo MEK dependence of AS-ERK2 substrates
Several of the AS-ERK2 substrates exhibit altered phosphorylation following MEK
inhibition. Pan et al. found reduced phosphorylation of AHNAK, ETV3, GIGYF2,PHLDB1,
RAI14, TNKS1BP1, and UBAP2L following treatment of EGF-stimulated HeLa cells with
U0126 (10). Kosako et al. found MEK-dependent phosphorylation of UDPGDH in 3T3-L1
fibroblasts (13), Old et al. found MEK-dependent phosphorylation of STK10 in the WM115
melanoma cell line (12), and Fritsche et al. found ERK-dependent phosphorylation of IRS2
(25). The combination of our in vitro results and the previously reported cell-based assays
supports these proteins as bona fide ERK2 substrates.
To identify additional phosphorylation sites affected by MEK inhibition in an unbiased
manner, we treated SILAC-labeled NIH 3T3-L1 fibroblasts with EGF or the phorbol ester
PMA with or without U0126 pretreatment (experiments 1 and 2 in table S2). Lysates were
digested with trypsin and antibodies recognizing the phosphorylated motifs PXpSP and
PXpTP were used to immunoprecipitate peptides containing potential ERK1/2 substrate
sites. A number of known ERK2 substrates were identified, including ERF and NUP153, as
well as the previously unknown AS-ERK2 substrate FOX2, a splicing factor (Fig. 4B).
Table S2 includes a complete list of the peptides identified in this experiment (experiments 1
through 3) and those from a similar experiment in 3T3-L1 adipocytes that also found MEK-
dependent phosphorylation of FOX2 following stimulation with insulin (experiment 4).
Regulation of ETV3 by phosphorylation
Ser139 of the transcriptional repressor ETV3 (also called METS and PE-1) was
phosphorylated by ERK2 despite lacking proline at the +1 position. Phosphorylation of this
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site was validated by MS/MS of the synthetic peptide (fig. S2), and an in vitro kinase
reaction confirmed that ERK2 phosphorylates ETV3 (Fig. 3C). We detected MEK-
dependent ETV3 phosphorylation in cells: Western blot analysis showed a MEK-dependent
gel shift in ETV3 in DLD1 colon carcinoma cells and in HEK 293T cell streated with PMA
compared with those treated with the MEK inhibitor U0126 (Fig. 4C and fig. S3A).
To determine whether ERK2 phosphorylates other sites on ETV3, we mapped
phosphorylation by LC-MS/MS following an in vitro kinase reaction. Eight phosphorylated
serine residues were detected, none of which were detected in a negative control (Fig. 4A).
Five of the eight sites are followed by proline; whereas two are PXpSAP motifs and one is
PXpSG. Although the noncanonical glycine may adopt a proline-like conformation, it seems
that proline at −2 and a small amino acid at +1 may be sufficient for recognition by ERK2.
Other groups have reported noncanonical sites phosphorylated by various MAPKs (26);
therefore, we suspect that these sites may be systematically overlooked because it is
uncommon to comprehensively map phosphorylation on putative kinase substrates.
ETV3 is related to ERF, another ETS domain-containing transcriptional repressor. ERF
translocates rapidly from nucleus to cytoplasm following phosphorylation by ERK1 or
ERK2 but ETV3 has been unresponsive to ERK1/2 activity in reporter gene assays (27). As
a result, ETV3 is thought to repress its transcriptional targets regardless of MAPK signaling.
Consistent with this previous observation, we detected predominantly nuclear localization of
ETV3 in 293T cells transfected with HA-tagged ETV3 regardless of phosphorylation state
(fig. S4). We observed the same result in DLD1 colon cancer cells treated with U0126 or
stimulated with the PMA and stained for endogenous ETV3(fig. S5).
To establish the transcriptional target sites of ETV3 and the effect of phosphorylation by
ERK2, we expressed human ETV3 with C-terminal HA-tag in HEK 293T cells and
performed ChIP-seq analysis. This experiment revealed several thousand binding sites
(tables S3, S4, S5), most of which were within 1 kilobase of known transcription start sites
(fig. S6), including previously reported binding near the beginning of the myc gene (Fig.
5A). We also observed binding near the beginning of etv3 itself,etv6 (table S5, also known
as tel), and ddx20, a partner required for ETV3 activity, suggesting that ETV3 negatively
regulates itself and related ETS factors (Fig. 5A) (28).We used THEME to identify DNA-
binding protein motifs near ETV3 binding sites and found that GGAA sequences
characteristic of ETS-family proteins were enriched (Fig.5B) (29).
Because phosphorylation by ERK eliminates the repressive activity of ERF, we
hypothesized that it might have a similar effect on ETV3. Intriguingly, 20 minute
stimulation with PMA led to an almost complete loss of DNA binding (Fig. 5A and 5C).
ChIP-PCR was used to confirm binding sites and showed strong phosphorylation-dependent
binding near ddx20 and dusp6, which encodes a MAPK phosphatase, and weak binding near
myc (Fig. 5C). The weaker binding near myc may reflect the relatively lower signal
observed by ChIP-seq. We verified by Western blot that the HA antibody captures ETV3 in
these ChIP experiments regardless of phosphorylation state (fig. S3B).Because serines at
positions 139, 159, 245, and 250 are homologous to ERK target residues in ERF, we tested
the effect of these residues in ETV3 on ERK-responsive DNA binding. Converting those
four sites to alanine reduced the PMA-induced gel shift by Western blot (fig. S3C) and
reduced the effect of ERK activity on DNA binding (Fig.5D). To test whether
phosphorylation impaired DNA binding or simply lead to degradation of ETV3, we
compared protein stability in 293T cells treated with cycloheximide and PMA or
cycloheximide, PMA, and U0126. ETV3 was constitutively unstable with a half-life of
approximately 2 hours, and was unaffected by the state of ERK activity (fig. S7).
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The transcriptional regulator STAT3 transiently up-regulates ETV3 mRNA and protein
expression in macrophages co-stimulated with interleukin-10 (IL-10) and lipopolysaccharide
(30). In the same work, overexpression of ETV3 repressed targets of the p65 (RelA) subunit
of the transcription factor NF-κB in COS cells. We identified ETV3 binding sites near many
genes encoding proteins involved in NF-κB signaling (nfkb2, nkap, nkiras1, nkiras2,
nfkbil1, trib3 and a weak signal near rela) (table S5). This set includes both positive and
negative regulators of NF-κB activity, suggesting that inactivation of ETV3 may be an
important step in priming the pathway to respond to other signals. ETV3 targets span a wide
range of other pathways and processes including ribosomal components and members of the
spliceosome (Bonferroni-correct p-value <10−4 using DAVID) (31, 32), and targets involved
in p53 signaling and cell cycle control (notably tp53, chek1, cdkn2a, e2f4, ccng2 and mdm4)
(table S5).
Discussion
Through an improved solid-phase capture chemical genetics strategy, we identified a large
number of known and previously unknown substrates of the AS-ERK2. These additional
newly identified substrates reveal a wide range of new connections between ERK2 and other
signaling pathways, including adaptors and signaling molecules, regulation and effector
proteins of the Rho guanosine triphosphatases (GTPases),transcription factors, splicing
regulators, and structural proteins. Validation using wild-type ERK2 showed that these
substrates were not artifacts of the Q103G mutation, and cell-based assays indicated that
many exhibited MEK-dependent phosphorylation and are, therefore, likely to be
physiologically relevant. Only 13 of the 80 substrates have been previously reported, and
these represent a small fraction of the approximately 200 reported substrates, suggesting that
ERK2 may phosphorylate a much larger number of proteins than previously recognized.
Comprehensive identification of these targets will require various complementary
technologies and detailed examination of many cell types.
Newly identified substrates expand the already considerable crosstalk between ERK1/2 and
other pathways. For example, regulation of cell shape and migration is mediated in part by
Rho GTPases, but few ERK1/2 substrates have been reported in Rho signaling pathways
(33). Identification of ERK2 substrate sites on the Rho guanosine-nucleotide exchange
factors (RhoGEFs) DOCK1 and ARHGEF17, the Rho GTPase activating protein (RhoGAP)
MYO9B, and the effector proteins CDC42EP1 and CDC42EP2 suggest that ERK2 regulates
these pathways both upstream and downstream from the Rho GTPases. The ERK2
phosphorylation sites on these proteins may provide previously unknown connections
between MAPK signaling and regulation of cell morphology and migration. Additional
investigation is needed to determine whether these phosphorylation sites function in normal
physiological regulation of cytoskeletal structure and cell shape, or in pathological
processes, such as cancer metastasis.
Phosphorylation of adaptor proteins may represent feedback loops by which ERK2 regulates
activity of the phosphatidylinositol 3-kinase (PI3K) to AKT pathway. Homology between
the residues phosphorylated by ERK2 on the adaptor in the insulin signaling pathway IRS2
and well-characterized sites on the related adaptor IRS1 suggests that phosphorylation by
ERK2 may modulate the effects of insulin signaling (34). In particular, Ser907 of mouse
IRS2 is ERK-responsive in hepatoma cells and liver tissue(25) and may have an functional
role. Because ERK is activated by insulin signaling, identification of additional ERK
phosphorylation sites raises the possibility that the kinase regulates IRS2 through several
modes of feedback. Any effect is likely to be part of normal feedback regulation associated
with insulin and other growth factor signaling, and could connect pathological ERK2
activation to insulin resistance caused by inflammation (35). ERK2-mediated
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phosphorylation of GIGYF2A, a GRB10-associated adaptor protein, is another potential
interaction with insulin signaling (36), although this protein is not as well characterized as
IRS2.
Another interesting point of crosstalk between ERK2 and other pathways is represented by
phosphorylation of the GLI2 transcription factor. Although the ERK2 phosphorylation site
has not previously been reported, it is proximal to residues near the C-terminus that are
phosphorylated by protein kinase A (PKA) and glycogen synthase kinase 3 (GSK3) to
regulate GLI2 stability, and therefore, may underlie the MEK-dependent crosstalk between
Hedgehog and EGF receptor signaling (37).
We showed that some of the newly identified substrates, including FOX2 and ETV3, are
phosphorylated by ERK2 in a cellular context. In vivo validation is important because
kinases are often promiscuous when removed from their biological environment, possibly
because of loss of regulation from subcellular localization and protein complexes. Some of
the phosphorylation sites identified in vitro have also been observed as MEK-dependent
phosphorylation sites in previous phosphoproteomics studies. The combination of in vitro
and cell-based assays will continue to be important in elucidating the structure of kinase
signaling networks.
ETV3 was the only ERK2 target that we identified with phosphorylation outside the
canonical S/TP motif. We found that ETV3 is extensively phosphorylated by ERK2 on at
least 8 serine residues, including three in noncanonical motifs. Although ETV3 has
previously been reported to be unaffected by ERK activity (27), we found that its DNA-
binding activity was rapidly abrogated by phosphorylation of ERK2 target residues. To
characterize this effect we used ChIP-SEQ to identify several thousand binding sites for
ETV3 across the genome, most of which contain an ETS consensus sequence, and all of
which were lost following ERK1/2 activation.
ETV3 target genes including etv3, ddx20, and dusp6 provide negative feedback regulation
of ETV3 production and activity. Negative feedback along with constitutive instability may
serve to tightly regulate ETV3 abundance. Our date suggest that phosphorylation by ERK2
relieves repression by ETV3, allowing activation of cell cycle control genes including myc,
components of the NF-κB pathway, and genes required form RNA processing and
translation. This concerted effect may prime cells to respond to additional stimuli, such as
IL-10 in bone-marrow derived macrophages (30). Once ERK2 activity ceases, newly
translated ETV3 can rapidly repress its target genes (Fig. 6),providing a transient burst of
transcriptional activity following ERK activation. We believe that previous work did not
observe an interaction between ERK and ETV3 because experiments focused on time-scales
of several hours, enough time for repression by ETV3 to be reestablished. Unlike ERF, a
related ETS repressor factor, loss of DNA binding by ETV3 does not appear to result from
sequestration in the cytoplasm. Although we have not observed phosphorylation of the ETS
domain itself, phosphorylation regulates many ETS domain-containing factors through
regulation of protein-proteininteractions or auto-inhibitory domains (38, 39). Interestingly,
loss of heterozygosity has been associated with the etv3 gene in B-cell chronic lymphocytic
leukemia and follicular lymphoma, suggesting that ETV3 functions as a tumor suppressor in
these cell types (40).Given the thousands of ETV3-phosphorylation-dependent targets,
ETV3 may thus function as a master regulator downstream of ERK activation in some cell
types, capable of modulating transcription of genes spanning a broad range of cellular
activities.
Further development of methods for analysis of thiophosphorylated peptides will continue to
expand the range of biological systems amenable to investigation by AS-kinases, and
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quantitative characterization of background labeling makes it possible to identify substrates
even in the presence of WT-kinase through the utilization of PhEt-ATPγS. We expect that
comparisons between cell types, growth factor treatments, or genetic perturbations will
reveal how MAPK signaling is rewired in different contexts.
Materials and Methods
Antibodies and reagents
Antibodies for phosphorylated ELK1, phosphorylated ERK1/2, phosphorylated motifs, anti-
HA Alexa488 conjugate, goat anti-rabbit Alexa488 conjugate, PMA, and recombinant
ERK2 were from Cell Signaling Technology. Normal rabbit IgG for immunofluorescence
was from Santa Cruz Biotechnology. Monoclonal rabbit antibody against alkylated
thiophosphate and p-nitrobenzylmesylate (PNBM) were from Epitomics. N6-(2-
Phenylethyl)adenosine-5’-O-(3-thiotriphosphate) (PhEt-ATPγS) was from Biolog (Bremen,
Germany). Adenosine-5’-O-(3-thiotriphosphate) (ATPγS), U0126,anti-HA agarose beads,
and the antibody recognizing ETV3 were from Sigma-Aldrich. The antibody recognizing
HA for ChIP was from Abcam. Media and amino acids for SILAC and iodoacetyl-agarose
beads were from Pierce/Thermo Scientific. EGF was from Peprotech. Q103G ERK2 (AS-
ERK2) with N-terminal HA tag was a gift from Dr. Roger Davis (University of
Massachusetts Medical School). HA-tagged human ETV3 was synthesized by GeneWiz Inc.
Genes for mammalian expression were cloned into the pBabe-puro-IRES-EGFP vector
(AddGene plasmid 14430)(41).
In vitro substrate labeling
Matched 3T3-L1 cells expressing WT-ERK2 or AS-ERK2 were generated by retroviral
transduction followed by puromycin selection, and 3T3-L1 cells were grown in DMEM
containing stable isotope labeled L-Lysine and L-Arginine, with 10% dialyzed fetal bovine
serum and 230 mg/L L-Proline. Cells were treated as indicated, washed with cold PBS and
lysed in 500 µL kinase buffer. Protein amounts were determined by BCA assay and lysates
were diluted to uniform concentration. Lysates were immediately supplemented with 1 mM
GTP and 50 µM N6-PhEt-ATPγS and incubated at 30°C for 30 to 90 minutes. Time-course
reactions were terminated by adding EDTA to 50 mM and placing the reaction on ice. For
Western blots, 13.5 µL of lysate was treated with 1.5 µL 25 mM PNBM in 50% DMSO for 2
hours.
Identification of thiophosphorylated peptides
Proteins from kinase reactions were precipitated in methanol/chloroform, suspended in
digest buffer by sonication in 100 mM NH4Ac pH 8.9, 1 mM CaCl2, and digested with
trypsin (1:100 w/w) overnight with rotation. Digests were acidified with acetic acid (1:6 v/
v), desalted on a C18 Sep-Pak (Waters), lyophilized, and resuspended at 20 mg/mL in
binding buffer (25 mM HEPES pH 7.0 in 50% ACN) with 1 mM TCEP and 250 µg/mL
bovine serum albumin (final pH 5.5). SulfoLink beads (25 µL per mg peptide) weree
quilibrated in binding buffer. Peptides were added to beads and rotated overnight in
darkness at room temperature. Beads were washed 2x in binding buffer, quenched with
DTT, and washed in binding buffer, 5% formic acid, and again in binding buffer. Beads
were loaded in a fused silica capillary (530 µm I.D.) and washed briefly with 0.1% acetic
acid. Peptides were eluted using 2 mg/mL potassium peroxomonosulfate (Oxone) directly
onto a POROS 20 R2 trapping column. The POROS column was washed with 0.2M acetic
acid and peptides were eluted with 70% ACN 0.2M acetic acid to a immobilized metal
affinity chromatography column (IMAC) for IMAC-LC-MS/MS analysis (21) on an LTQ-
Orbitrap XL mass spectrometer (ThermoFisher Scientific). A detailed protocol is available
in the Supplementary Methods. Data files were converted to MASCOT generic format (mgf)
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using DTASuperCharge (version 1.19) and searched using MASCOT(22)(version 2.1)
against the NCBI mouse proteome using peptide tolerance of 12 ppm and MS/MS tolerance
of 0.7 Da. Peptide identification and phosphorylation site assignments were manually
validated to ensure correct identification and quantitation. Any peptide with a low-
confidence assignment was confirmed by comparison to a synthetic peptide.
Phosphorylation motif peptide immunoprecipitation
SILAC-labeled fibroblasts were pretreated with either 5 or 10 µM U0126 for 10 minutes and
then stimulated with EGF (100 ng/mL) for 20 minutes. Differentiated 3T3-L1 adipocytes
were produced as described (42). Adipocytes were pretreated with U0126 at 10 µM for 10
minutes and then with insulin at 150 nM for 15 minutes. Cells were lysed with a solution
containing 8 M urea with 1 mM Na3VO4 and processed as described for peptide labeling
with 4-plex iTRAQ reagents (AB Sciex). Samples were dissolved (Tris-HCl pH 7.4, 0.03%
NP40), immunoprecipitated with antibodies against PXpSP and PXpTP phospho-motifs, and
analyzed by IMAC-LC-MS/MS using an LTQ-Orbitrap XL or QStar XL (AB Sciex) mass
spectrometer (for fibroblasts or adipocytes respectively) as described (42).
Chromatin immunoprecipitation and high-throughput sequencing (ChIP-Seq)
Three 15-cm plates of HEK 293T cells were transfected with HA-tagged human ETV3 (20
µg plasmid, 60 µL FuGene HD in 0.5 mL PBS) and incubated for two days to a density of
2.5 × 107 cells per plate. Cells were treated for 20 minutes with U0126 (10 µM) with or
without PMA (100 nM). A control experiment was conducted with non-transfected cells.
The ChIP protocol was modified from methods previously described (43, 44). Briefly,
frozen pellets of formaldehyde-fixed cells were resuspended and lysed. The cells were then
sonicated using a Misonix Sonicator 3000 at 33W for twelve cycles of a 20-second pulse
followed by a 60-second pause. Lysate was centrifuged at maximum speed in a microfuge
for 10 minutes at 4°C to remove impurities. The lysate was incubated with 50 µL of Dynal
Protein G magnetic beads bound to 10 µg of antibody for 15 hours at 4°C. The purified
DNA was prepared for sequencing on a Beckman Coulter SPRI-TE following
manufacturer’s instructions. The seq-prepped DNA was PCR amplified using Illumina
primers for 18 cycles. Samples were sequenced using Illumina Solexa Genome Analyzers
2.0. Reads were mapped to the hg18 reference genome using the GERALD alignment
software package. Uniquely mapping reads were run through the MACS v1.4.0beta peak
calling software using default parameters. Reads from 293T cells transfected with ETV3-
HA and treated with U0126 were used as the foreground and untransfected 293T cells as the
background. Resulting peaks were filtered for p-value < 1e-10. Peaks were mapped to
UCSC Known Genes if they fell within a 10kb window around a gene’s transcription start
site. ChIP-Seq data has been uploaded to the NCBI Sequence Read Archive.
ChIP-qPCR
8 × 106 293T cells were prepared and processed as described for ChIP-Seq experiments,
except that only 106 cells and 5 µg of antibody were used. Samples were analyzed by real-
time PCR on a Roche Lightcycler 480 system using Roche SYBR Green I PCR master mix.
Primers for ddx20 were 5’ GAGGCGGAGATACGAACT TG 3’ and
5’TACCACATTGGCTGGTGTGT 3’, for dusp6 5’ GCTGGAACAGGTTGTGTTGA 3’and
5’ AAGTGCCCTGGT TTATGTGC 3’, and for myc 5’ CCAACAAATGCAATGGGAGT
3’ and 5’ CCAGAGTCCCAGGGAGAGTG 3’.Mutations in the ETV3-pBabe-IRES-EGFP
vector were introduced using Stratagene QuikChange.
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Recombinant ERK2 substrates and in vitro kinase reactions
Clones were from OpenBiosystems (clone IDs ETV3: 4918332, RIPK3: 3590770,STK10:
40111177, NID1: 40110859, RBMPS: 3586451), except CDC42EP1 (OriGene catalog
#MC205344) and IRS2 (Addgene plasmid 11373). CDC42EP1, ETV3, NID1,RBPMS, and
RIPK3 were cloned into pET-16b (Stratagene), and IRS2 and STK10 were inserted into
pET-100 (Invitrogen) using directional TOPO cloning. Vectors were transformed into BL21
Star (DE3) E.coli (Invitrogen) and induced with 1 mM IPTG for three hours during log-
phase growth of a 2 mL culture. Bacterial pellets were lysed using B-Per bacterial lysis kit
with DNAase, lysozyme, and Halt protease inhibitors (Thermo Scientific). Recombinant
proteins were recovered from inclusion bodies by solubilization in 8M urea, except RIPK3,
which was solubilized with 0.2% sodium dodecyl sulfate in 40 mM Tris-HCl pH 7.5, 100
mM NaCl. Recombinant proteins were stored at 10 ng/µL in 20 mM Tris-HCl pH 7.5, 50
mM NaCl, 50% glycerol.
Kinase reactions used 10–30 ng of substrate, 12.5–25 ng recombinant ERK2, and ATPγS at
50–100 µM in kinase buffer (25 mM Tris-HCl pH 7.5, 5 mM β–glycerolphosphate, 2 mM
dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2) and were incubated 30 minutes at 30°C.
Reactions with RIPK3 were supplemented with 100 mM thiourea to increase solubility. Half
of each reaction was silver stained as a loading control; half was treated with PNBM at 2.5
mM for two hours prior to Western blotting for thiophosphate.
Phosphorylation mapping of recombinant proteins by HPLC-MS/MS
Kinase reactions were performed for 1 hour with approximately 100 ng of each substrate
and 100 µM ATP. Matched negative control reactions omitted ATP. Each reaction was run
by SDS-PAGE and proteins visualized by Coomassie stain or mass-spectrometry compatible
silver stain (Thermo Scientific). Matched bands were cut and destained, and processed as
described in (45) for overnight digestion in trypsin (Promega, 12.5 ng/uL in 50 mM
ammonium bicarbonate pH 8.9) or chymotrypsin (Sigma-Aldrich, 125 ng/uL in 100 mM
Tris 10 mM CaCl2 pH 8.0 at 30°C). Reactions were quenched with 5% formic acid in 50%
acetonitrile and peptides were eluted by dehydrating the gel band twice with 100%
acetonitrile. Peptide samples were dried to about 2 µL in a vacuum centrifuge and
resuspended in 30 µL 0.1% acetic acid.
IMAC (21) was used to enrich phosphopeptides from digests of CDC42EP1 and IRS2, and
ETV3 was loaded directly onto a C18 pre-column (10 cm, 100 µm internal diameter (I.D.).
Pre-columns were placed in-line on an HPLC connected to a C18 column with electrospray
tip (10 cm, 50 µm I.D., 1 µm tip flowing at approximately 20–40 nL/min). Peptides were
eluted using a piece-wise linear gradient from 0% to 70%acetonitrile in 0.2M acetic acid (4
min: 9.1%, 50 min: 29.4%, 57 min: 42%, 60 min: 70%)and analyzed on an Orbitrap XL
hybrid mass spectrometer. The mass spectrometer was running in data-dependent mode
where each cycle included an Orbitrap MS scan with 100,000 target resolution followed by
isolation and Collision-induced Dissociation of up to six ions (charge state 2–5) for analysis
in the LTQ ion trap. MS/MS spectra were extracted using DTASuperCharge (version 1.19)
and identified by MASCOT (Matrix Science, version 2.1). Phosphorylated peptides were
confirmed by manual inspection of each spectrum and peak annotations are shown in in the
Supplementary Spectra.
Immunofluorescence
Approximately 105 per cm2 of DLD1 or HEK 293T cells were thoroughly dispersed and
plated overnight on coverslips. HEK 293T cells were then transfected with HA-tagged
mouse ETV3 in the pBabe-IRES-EGFP vector (AddGene vector 14430) using FuGene HD
(Roche) according to the manufacturer’s instructions and grown for two more days. Cells
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were treated as indicated in the figure with U0126 (10 µM) in the presence or absence of
PMA (100 nM), fixed in 4% formaldehyde for 15 minutes, and washed 3 times with PBS.
Cells were blocked for one hour with 5% goat serum (DLD1) or 5%mouse serum (HEK
293T) in PBS with 0.1% Triton-X. DLD1 cells were incubated overnight at 4°C with the
antibody recognizing ETV3 at 8 µg/mL in PBS with 1% BSA and 0.1% Triton-X, then
washed three times with PBS and incubated for 1 hour with anti-rabbit Alexa488 secondary
antibody at 1:1000 dilution with goat anti-rabbit Alexa488 conjugate. Following antibody
incubations, slides were washed twice with PBS, treated with DAPI in PBS for 15 minutes,
washed once with PBS, treated with phalloidin conjugated to Alexa647 (Invitrogen), washed
twice with PBS, and mounted on slides using ProLong Gold (Invitrogen). Images were
captured on a DeltaVision Spectris microscope from Applied Precision and processed by
software deconvolution.
ERK binding site motif analysis
ScanSite 2.0 (http://scansite.mit.edu) was used to search SwissProt protein sequences for
high-stringency ERK1/2 binding sequences (ScanSite motifs “Erk D-domain” and “Erk1
Binding” for D-domain and DEF-domain, respectively) (46) . Where an appropriate protein
sequence was not available in SwissProt, protein sequences were uploaded directly from the
National Center for Biotechnology Information Entrez protein database. The frequency of
each motif in AS-ERK2 substrates was compared to SwissProt mouse proteome (22 Sept
2009 release) using the X2-test.
ETV3 binding motif analysis
To identify an optimal ETV3 binding motif, we searched DNA sequences under ChIP-Seq
peaks from the U0126-treated condition for TRANSFAC motifs recognized by ETS family
by transcription factors. The motif recognized by ELK-1 was most highly enriched so it was
used as the initial hypothesis for motif refinement. The strength of peak signals, as
determined by p-value from MACS, was highly correlated with the quality of their match to
the ELK-1 binding motif. Peaks with a MACS p-value lower than 1e-25 contained ELK-1
binding motifs with better scores than the median motif score observed in a randomly
sampled set of background sequences that matched the distributions of the U0126 peaks in
terms of length, guanine-cytosine content, and distance from a transcription start site. We
then refined the ELK-1 motif using the sequence of the peaks that passed this threshold as
input to THEME (29).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Identification of direct substrates of AS-ERK2
(A) Substrates of AS-ERK2 were thiophosphorylated in cell lysate, digested, and covalently
coupled to iodoacetyl-agarose beads. Phosphopeptides were recovered by oxidative
hydrolysis and further enriched by IMAC prior to analysis by LC-MS/MS. (B) Activated
wild-type (WT) and AS-ERK2 phosphorylate a known substrate (ELK1). Activated kinases
were immunoprecipitated and incubated with ELK1-GST and 50 µM ATP or N6-PhEt-
ATPγ Sin kinase buffer for 15 minutes at 30°C. (C) Thiophosphorylation of kinase
substrates occurs in lysate of AS-ERK2-expressing cells to a greater extent than occurs in
WT-ERK2-expressing cells. 3T3-L1 fibroblasts expressing WT- or AS-ERK2 were
stimulated with PMA for 3 minutes or treated with U0126 for 20 minutes followed by PMA
and lysed in kinase buffer and thiophosphorylation reactions were carried out for the
indicated times. Thiols were alkylated by PNBM followed by Western blot for
thiophosphate ester. (D) Quantification of the total signal for each lane from panel C,
demonstrating the level and MEK-dependence of the background thiophosphorylation in
WT-ERK2 expressing cells. (E) SILAC-labeled peptides provide a quantitative basis to
determine whether a given phosphorylation site is a direct ERK2 substrate, with examples of
background phosphorylation), a known ERK2 substrate, and two newly identified substrates.
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Fig. 2. Analysis of AS-ERK2 substrates
(A) Functional classifications for proteins identified as substrates of AS-ERK2 on the basis
of analysis of Gene Ontology (GO)terms, UniProt annotation, and literature review. Proteins
in red are previously reported ERK2 substrates, proteins in bold have in vivo evidence of
MEK-dependent phosphorylation. (B) AS-ERK2 substrate localization based on “Cellular
Component”annotations from GO, giving priority to experimental over automated
annotations. Proteins annotated as both nuclear and cytoplasmic are shown as cytoplasmic/
nuclear
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Fig. 3. Validation of AS-ERK2 substrates
(A) AS-ERK2 substrates are enriched for ERK1/2-binding motifs. Substrate protein
sequences were analyzed by ScanSite (http://scansite.mit.edu) for the presence of ERK 1/2
binding domains with high stringency. The bar plot compares the frequency of high
stringency D-domains and DEF-domains between AS-ERK2 substrates and the entire
SwissProt mouse proteome., P-values were calculated using a χ 2 -test. (B) Amino acid
frequencies around the phosphorylation site are similar for known ERK2 substrates (top
plot) and for targets of AS-ERK2 (bottom plot). (C) Newly identified substrates were
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expressed in E.coli and phosphorylated by wild-type ERK2 through in vitro kinase
reactions.
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Fig. 4. Phosphorylation of FOX2 in a biological context and wide-spread phosphorylation of
ETV3 by ERK1/2
(A) Phosphorylation sites identified on recombinant ETV3 following in vitro kinase reaction
with ERK2, along with the four amino acids surrounding the phosphorylated site to show the
similarity of each site to theoptimal ERK1/2 motif (PX[S/T]P). (B) Phosphorylated ERK2
substrate peptide from theFOX2 splicing factor detected by peptide immunoprecipitation in
SILAC-labeled 3T3-L1fibroblasts. The three signals represent cells treated with PMA,
U0126, or U0126 followed by PMA as indicated. (C) ETV3 exhibits a MEK-dependent gel
shift in DLD1cells treated with PMA, U0126, or U0126 pre-treatment followed by PMA.
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Fig. 5. Phosphorylation by ERK2 prevents DNA binding by ETV3
(A) Example data from several genes identified by chromatin immunoprecipitation of HA-
tagged ETV3followed by high-throughput sequencing. Cells treated with PMA (100 nM) for
20minutes display minimal binding of ETV3 to DNA; cells treated with U0126 (10 µM)
for20 minutes yielded several thousand binding sites for ETV3. (B) ETV3 binds a GGAA-
containing sequence characteristic of ETS-domain proteins. The most strongly enriched ETS
family motif (ELK-1) from TRANSFAC was refined using THEME on high-confidence
binding sites (p < 1 × 10−32). (C) ChIP and quantitative PCR for binding sites near myc,
ddx20, and dusp6 from ETV3-transfected 293T cells treated as in panel D (N = 6, error bars
S.E.M). Greater enrichment of ddx20 and dusp6 is observed in non-phosphorylated and
partially phosphorylated conditions (* p <0.01, t-test in log-space).(D) Converting serines
139, 159, 245, and 250 (4SA) to alanine reduces the effect of phosphorylation on DNA
binding (N = 4, error bars S.E.M).
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Fig. 6.
A model for rapid regulation of ETV3 by phosphorylation followed by downstream effects,
including negative feedback through increased transcription of etv3,ddx20, and dusp6.
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